IFP Advisors Inc Boosts Stock Position in Insulet Corporation $PODD

IFP Advisors Inc raised its position in Insulet Corporation (NASDAQ:PODD) by 7.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,358 shares of the medical instruments supplier’s stock after buying an additional 93 shares during the quarter. IFP Advisors Inc’s holdings in Insulet were worth $472,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Nissay Asset Management Corp Japan ADV raised its stake in shares of Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after purchasing an additional 48 shares during the period. Mather Group LLC. raised its stake in shares of Insulet by 4.4% during the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after purchasing an additional 48 shares during the period. Brooklyn Investment Group raised its stake in shares of Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock valued at $209,000 after purchasing an additional 52 shares during the period. Cooper Financial Group increased its stake in Insulet by 5.7% in the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 58 shares during the last quarter. Finally, HighTower Advisors LLC increased its stake in Insulet by 2.1% in the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier’s stock worth $757,000 after acquiring an additional 60 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PODD shares. Morgan Stanley restated an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Citigroup restated a “buy” rating on shares of Insulet in a research note on Tuesday, July 8th. Leerink Partners upped their target price on Insulet from $339.00 to $355.00 and gave the stock an “outperform” rating in a research note on Tuesday. JPMorgan Chase & Co. upped their target price on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Finally, Piper Sandler upped their target price on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Eighteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $348.05.

Insulet Price Performance

PODD opened at $318.30 on Wednesday. The stock has a 50-day moving average price of $325.03 and a 200-day moving average price of $301.15. Insulet Corporation has a 12-month low of $226.50 and a 12-month high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $22.41 billion, a P/E ratio of 96.75, a PEG ratio of 2.63 and a beta of 1.40.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.